A research team at the University of Cologne’s Center for Molecular Medicine Cologne (CMMC) has discovered that the protein cFLIP can be used to override the defenses of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. These defenses often cause treatments to be ineffective because they allow the cancer cells to survive. The results are especially relevant to ABC-DLBCL, a specific subtype of blood cancer that has poor patient prognosis and survival outcome. The new study appeared under the title “Expression of cFLIP in B cells is essential for diffuse large B cell lymphoma pathogenesis” in the Blood Journal.
Continue Reading this article here
